◆ NeutralJNJMDTABTSYKBSX
Why Did J&J Stock Fall After Q3 Earnings Despite Raised Guidance?
Zacks Investment Research·
Johnson & Johnson's shares fell 5.8% after Q3 2026 results showed earnings beat but sales missed expectations. MedTech segment underperformed with only 2.5% growth due to Abiomed declines and international market challenges, while Innovative Medicine remained strong. Despite headwinds, J&J raised full-year guidance and targets over $100 billion in 2026 revenue with accelerated growth expected in 2027.
Read Full Article at Zacks Investment Research →